Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698214 | 0.90 | MAPT (0.66) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL10111817 | 0.88 | MAPT (0.72) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2695809 | 0.88 | ABL1 (0.56) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2697452 | 0.87 | MAPT (0.58) | MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2697469 | 0.86 | TRPA1 (0.62) | MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2694516 | 0.86 | MAPT (0.58) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL9933508 | 0.84 | MAPT (0.80) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2695180 | 0.82 | MAPT (0.66) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2694928 | 0.80 | MAPT (0.56) | ABL1MAPTSMN1; SMN2TRPA1LMNA | |
| SCHEMBL2696354 | 0.80 | MAPT (0.56) | ABL1MAPTSMN1; SMN2TRPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311248-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-11-01 | — | — | US | disclosed |
| US-9980968-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980968-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980968-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | ELI LILLY AND COMPANY | 2017-06-01 | — | — | US | disclosed |
| US-20160354379-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2016-12-08 | — | — | US | disclosed |
| US-20160354379-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2016-12-08 | — | — | US | disclosed |
| US-20160354379-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2016-12-08 | — | — | US | disclosed |
| US-9260431-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140303192-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20130165454-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165454-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8318728-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318728-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318728-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120108613-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120108613-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120108613-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2010039289-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009158719-A2 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303192-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ABL1 970/4885MAPT 2844/4885SMN1; SMN2 1895/4885 |
| US-20160354379-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ABL1 970/4885MAPT 2844/4885SMN1; SMN2 1895/4885 |
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | TRPA1, TRPV1, TRPV2 | ABL1 1793/4885MAPT 3623/4885SMN1; SMN2 2024/4885 |
| US-20130165454-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES | CASP3, MGMT, ELANE | ABL1 252/4885MAPT 1662/4885SMN1; SMN2 2791/4885 |
| US-20180311248-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ABL1 970/4885MAPT 2844/4885SMN1; SMN2 1895/4885 |
| US-20120108613-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ABL1 970/4885MAPT 2844/4885SMN1; SMN2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.